Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pooled Purchasing Is Poor Answer To Latin American Drug Pricing Worries, Says Industry

Executive Summary

Pooled procurement will not fix problems relating to affordability and access to medicines in South America, says the US pharma industry association, PhRMA, in response to news that Mercosur trade bloc members will join forces to negotiate better prices for medicines.

You may also be interested in...



Mercosur Bets On Joint Pricing Negotiations And Procurement For Lower Prices, But Slams Hep C Companies

Countries in South America have negotiated lower prices for the immunosuppressant tacrolimus and have their sights on high-cost oncology treatments. However, they have slammed companies selling new hepatitis C treatments for their inflexibility.

More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab

Biocon and Mylan have received approval in Brazil for the first biosimilar version of Roche’s Herceptin (trastuzumab). The partners hope to provide an “affordable” option, expanding access to the product in the Latin American nation.

More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab

Biocon and Mylan have received approval in Brazil for the first biosimilar version of Roche’s Herceptin (trastuzumab). The partners hope to provide an “affordable” option, expanding access to the product in the Latin American nation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121306

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel